In theory, SRPIN340 treatment could inhibit the synthesis of PIK3CD-S variant through blocking the exon 20 skipping in PIK3CD pre-mRNA, thereby enriching the PIK3CD-L (which is sensitive to Idelalisib treatment) in these cancer cells. Here, PIK3CD is linked to cancer.